Patent Grant
11484723
The present invention relates to neurostimulation treatment systems and associated devices, as well as methods of treatment, implantation and configuration of such treatment systems.
Treatments with implantable neurostimulation systems have become increasingly common in recent years. While such systems have shown promise in treating a number of conditions, effectiveness of treatment may vary considerably between patients. A number of factors may lead to the very different outcomes that patients experience, and viability of treatment can be difficult to determine before implantation. For example, stimulation systems often make use of an array of electrodes to treat one or more target nerve structures. The electrodes are often mounted together on a multi-electrode lead, and the lead implanted in tissue of the patient at a position that is intended to result in electrical coupling of the electrode to the target nerve structure, typically with at least a portion of the coupling being provided via intermediate tissues. Other approaches may also be employed, for example, with one or more electrodes attached to the skin overlying the target nerve structures, implanted in cuffs around a target nerve, or the like. Regardless, the physician will typically seek to establish an appropriate treatment protocol by varying the electrical stimulation that is applied to the electrodes.
Current stimulation electrode placement/implantation techniques and known treatment setting techniques suffer from significant disadvantages. The nerve tissue structures of different patients can be quite different, with the locations and branching of nerves that perform specific functions and/or enervate specific organs being challenging to accurately predict or identify. The electrical properties of the tissue structures surrounding a target nerve structure may also be quite different among different patients, and the neural response to stimulation may be markedly dissimilar, with an electrical stimulation pulse pattern, pulse width, frequency, and/or amplitude that is effective to reduce affect a body function one patient potentially imposing significant discomfort or pain on, or have limited effect for, another patient. Even in patients where implantation of a neurostimulation system provides effective treatment, frequent adjustments and changes to the stimulation protocol are often required before a suitable treatment program can be determined, often involving repeated office visits and significant discomfort for the patient before efficacy is achieved. While a number of complex and sophisticated lead structures and stimulation setting protocols have been implemented to seek to overcome these challenges, the variability in lead placement results, the clinician time to establish suitable stimulation signals, and the discomfort (and in cases the significant pain) that is imposed on the patient remain less than ideal. In addition, the lifetime and battery life of such devices is relatively short, such that implanted systems are routinely replaced every few years, which requires additional surgeries, patient discomfort, and significant costs to healthcare systems.
While rechargeable implanted devices have been investigated, the location and depth at which neurostimulation devices are implanted makes recharging of such devices difficult. For example, neurostimulation devices are typically implanted beneath a thin layer of muscle and fatty tissues in a lower back region such that conventional methods may utilize invasive techniques, such as recharging through a transcutaneous cable, or increased device size which may cause discomfort and limited mobility for the patient. Furthermore, given the location at which such devices are implanted—the lower back—attaching a recharging cable or device can be difficult, if not impossible, for a patient to perform without the aid of another person.
In view of these drawbacks associated with conventional systems, the tremendous benefits of these neural stimulation therapies have not yet been fully realized. Therefore, it would be desirable to provide improved methods, systems and devices for facilitating recharging of an implanted neurostimulation device. It would be particularly helpful to provide such systems and methods that recharge an implanted neurostimulation device in a non-invasive manner, while improving ease of use for the patient as well improved patient comfort and mobility during charging.
Systems, devices and methods of the invention presented herein pertain to transcutaneous charging of an implanted medical device. In particular, the invention pertains to device and methods that facilitate positioning and alignment of a charging device and affixation of the charging device in the proper position and/or alignment to the patient.
In one aspect, a rechargeable medical implant system in accordance with embodiments of the invention includes: an implantable medical device having a rechargeable power source for powering the device while implanted within a patient and a wireless power receiving unit coupled with the rechargeable power source; a portable charging device having a wireless power transmitting unit configured to magnetically couple with the wireless power receiving unit of the implantable device so as to recharge the rechargeable power source; and a carrier removably coupleable with the charging device, the carrier having an adhesive surface for adhering to a skin surface of the patient, wherein the adhesive surface includes a biocompatible adhesive with sufficient adhesive strength to adhere to the patient's skin surface and support the carrier coupled with the charging device for at least a duration of time sufficient to recharge the implanted medical device. The wireless power transmitting unit of the charging device includes a charging coil configured for magnetically coupling with the wireless receiving unit when the charging device at least partially engages the patient's skin surface and is positioned at least partially over the implantable medical device, wherein the carrier secures the charging device substantially flat against the patient's skin.
In some embodiments, a carrier device in accordance with aspects of the invention includes one or more movable tabs on which an adhesive surface is disposed, each of the one or more tabs being movable between a first position and a second position when the carrier is coupled with the charging device placed against the patient's skin. In the first position, the one or more tabs are spaced away from the patient's skin to facilitate manual positioning of the charging device along the patient's skin. In the second position, the one or more tabs are urged against the patient's skin to facilitate secure attachment of the carrier to the patient's skin with the adhesive surface for the duration of charging.
In some embodiments, the carrier device includes one or more tabs extend circumferentially, at least partly, about the charging device when the carrier is coupled with the charging device so as to secure the charging device substantially flat against the patient's skin when the carrier is adhered to the skin of the patient. The carrier may include a frame to which one or more tabs are attached, wherein the frame defines a mounting interface at which the charging device is removably coupled. The mounting interface of the carrier is configured to allow manual rotation of the charging device relative to the carrier while releasably coupled with the carrier.
In one aspect, the carrier includes a mounting interface configured with a dimensional fit that allows rotation of the charging device when the charging device is subjected to a moment force and sufficient friction to maintain angular fixation of the charging device within the carrier when the charging device is static. In some embodiments, the charging device is defined by a circular or puck-shaped housing supporting and/or encasing the wireless power transmitting unit and associated charging coil at least partially within a protruding circular portion of the housing. The frame of the carrier comprises a circular ring and the mounting interface comprises a ridge along an inside edge of the circular ring that interfaces with an outer edge of the protruding portion of the charging device. The mounting can be configured to resiliently receive the protruding circular portion of the charging device within a snap-fit.
In some embodiments, the carrier device includes three or more tabs disposed circumferentially about a central frame of the device and extending laterally outward from the frame, each tab being deflectable between first and second positions. In one aspect, the tabs are formed of a material that is sufficiently stiff and flexible to resiliently invert (pass over center) between the first and second positions. The frame and the one or more tabs can be integrally formed of a polymeric material and may be disposable.
In one aspect, the carrier device includes a coupling interface that releasably couples to the charger device and has one or more movable tabs having adhesive portions for securely adhering to a skin of the patient, the adhesive portions being isolated from the charger device. In some embodiments, the adhesive portions are disposed on the one or more tabs so that the adhesive portions are not in contact with a surface of the charging device. Such a configuration is advantageous as it avoids accumulation of residual adhesive on the charger device, which is re-used over many charging sessions.
In another aspect, the charger device can be disposable, the adhesive portions providing secure attachment to the patient for at least a sufficient duration of time to charge the device. The carrier device can then be readily removed from the charger device and discarded or recycled after the charging session is complete. In some embodiments, the carrier device is provided to a patient with one or more liners disposed over the adhesive portions to preserve and protect the adhesive until ready for use. A single liner that extends over all adhesive portions can be used so that the charger device can be secured and the single liner removed thereby exposing all adhesive portions. In some embodiments, the patient is provided with multiple disposable carrier devices, such as a pack of carrier devices.
In another aspect, a carrier device for a portable charging device configured for transcutaneous charging of an neurostimulator device implanted in a patient is provided herein. Such carrier devices can defined by a semi-rigid or rigid frame configured for removably coupling with the charging device, wherein the frame includes an opening through which a portion of the charging device extends when the charging device is coupled with the frame; and one or more tabs attached to the frame and extending laterally outward from the opening of the frame, wherein the one or more tabs include an adhesive surface having a biocompatible adhesive with sufficient adhesive strength to adhere to a skin surface of the patient and support the carrier coupled with the charging device for a duration of time sufficient to recharge the implanted neurostimulator. Each of the one or more tabs is movable between a first position and a second position when the carrier is coupled with the charging device placed against the patient's skin, wherein in the first position, the one or more tabs are spaced away from the patient's skin to facilitate manual positioning of the charging device along the patient's skin and, in the second position, the one or more tabs are urged against the patient's skin to facilitate secure attachment of the carrier to the patient's skin with the adhesive surface for the duration of charging. Such carrier devices may include any of the features described in the systems above.
In some embodiments, the charging device carrier includes a frame defined by a circular ring having a circular opening dimensioned to fittingly received a circular protruding portion of the charging device having a charging coil therein. The carrier includes one or more tabs disposed circumferentially about the opening that extend laterally outward as to support and maintain the charging device substantially flat against the patient's skin when the charging device is coupled to the carrier and the tabs are adhered to the skin of the patient.
Methods of transcutaneously charging an implanted medical device in a patient in accordance with aspects of the invention are also provided herein. Such methods includes steps of: removably coupling a portable charging device having a housing and a charging coil disposed therein with a carrier having one or more tabs with a biocompatible adhesive surface, the one or more tabs being movable between a first position and a second position; non-invasively engaging a bottom surface of the charging device at least partially against a skin surface of the patient while mounted within the carrier with the one or more tabs in the first position spaced a distance away from the skin surface of the patient; positioning the charging device until it is at least partially positioned over or proximate the implanted medical device; and moving the one or more tabs from the first position to the second position so that the adhesive surface contacts and adheres to the skin of the patient sufficiently to support the charging device coupled with the carrier for a duration of time sufficient to charge the implanted device.
In some embodiments, positioning the charging device includes moving the charging device along the skin surface of the patient near the implanted device until the charging device outputs user feedback that indicates to the patient that the charging device is properly positioned. Typically, the first alert can be audible and/or haptic user feedback. The method may further include rotating the charging device relative to the carrier while the one or more tabs secure the carrier to the skin surface of the patient until the charging device is rotationally aligned with the implanted device, which may be indicated by user feedback, such as a second alert. In one aspect, each of engaging the bottom surface of the charging device with the skin of the patient, positioning the charging device, rotating the charging device relative the carrier, and moving the one or more tabs to the second position is performed with a single hand of the patient, thereby providing improved patient comfort and ease of use.
In some embodiments, the charge device carrier includes a belt. The belt can be formed of a breathable stretchable material and include a corresponding coupling feature on each opposing end adapted to releasably couple with each other to allow a patient to adjust the belt to a mid-section as desired. A circular aperture can be disposed in an intermediate portion of the belt. The circular aperture is dimensioned to fittingly receive a protruding circular portion of the portable charging device. A semi-rigid or rigid frame circumscribes the circular aperture and has a mounting interface adapted for removably coupling with the charging device so that the protruding circular portion of the charging device protrudes through the circular aperture and engages skin of the patient when the charging device is coupled to the belt worn on the mid-section of the patient. In some embodiments, the mounting interface is axisymmetric about a normal axis extending through a center of the circular aperture so as to allow the patient to manually rotate the charging device when coupled with the belt to a particular rotational alignment.
In some embodiments, methods of transcutaneously charging an implanted medical device in a patient include removably coupling a portable charging device having a housing and a charging coil within a carrier belt having a circular aperture so that the circular bottom portion protrudes through the aperture when coupled. A bottom surface of the charging device is non-invasively engaged with at least partially against a skin surface of the patient while mounted within the carrier belt. The charging device is positioned by the patient until at least partially positioned over or proximate the implanted medical device as indicated by a first audible and/or haptic signal from the charging device. The belt is adjusted by releasably coupling corresponding coupling features on opposite ends of the belt. The belt can be positioned before, during or after positioning of the charging device by the patient. The method can further include manually rotating the charging device while coupled within the belt until a second audible and/or haptic signal indicates an acceptable charging alignment for charging.
In one aspect, a method of transcutaneously charging an implanted medical device in a patient includes use of different indicators (e.g. audible and/or haptic alerts) to assist a patient in charging of the implanted medical device with a portable charging device. Such methods can include: placing a portable charger device on the patient to facilitate charging of an implanted neurostimulation within the patient; positioning the portable charger device until the charging device outputs a first indicator to the patient indicating that the charging device is proximate or suitably positioned over the implanted device for charging; adjusting a position of the portable charger device or an attachment device supporting the charger device in response to a second indicator output by the charging device indicating an interruption in charging; and removing the charging device after a third indication is output by the charging device indicating completion of charging. Typically, each of the first, second and third indicators is unique so as to be readily identifiable by the patient. Each of the first, second and third indicators can be an audible alert and/or a haptic alert. In some embodiments, the first alert is a sustained tone. The second indicator can be a periodic vibration and/or a series of short tones, such as three beeps and vibration repeated every few seconds. The third indicator can include a repeating series of short tones that is different from that of the second indicator, for example, a series of rising tones that repeats, to alert the patient that charging is complete so that the charging device can be removed.
In another aspect, a system in accordance with the invention can include an implantable medical device and a portable charging device having an indicator graphic for visually representing a target alignment of the charging device relative the implanted medical device. Such a system can include an implantable medical device having a rechargeable power source for powering the device while implanted within a patient and a wireless power receiving unit coupled with the rechargeable power source; and a portable charging device having a wireless power transmitting unit configured to magnetically couple with the wireless power receiving unit of the implantable device for recharging of the rechargeable power source. The portable charging device can include a planar surface for engaging a skin of the patient over the implanted medical device to facilitate charging. The indicator graphic can be provided on the planar surface and/or on the opposing outward facing surface and represent a target alignment of the charging device relative the implanted medical device to facilitate alignment of the charging device by the patient. The indicator can be a graphic that is the size and shape (e.g. outline) of the implanted medical device, which can serve as a visual prompt or reminder to the patient as to the desired alignment of the charging device relative the implanted medical device. The system can further include a carrier device for supporting the charging device in the desired alignment, such as in any of the embodiments described herein.
Further areas of applicability of the present disclosure will become apparent from the detailed description provided hereinafter. It should be understood that the detailed description and specific examples, while indicating various embodiments, are intended for purposes of illustration only and are not intended to necessarily limit the scope of the disclosure.
The present invention relates to neurostimulation treatment systems and associated devices, as well as methods of treatment, implantation/placement and configuration of such treatment systems. In particular embodiments, the invention relates to sacral nerve stimulation treatment systems configured to treat bladder dysfunctions, including overactive bladder (“OAB”), as well as fecal dysfunctions and relieve symptoms associated therewith. In addition, the descriptions herein may also be used to treat other forms of urinary dysfunction and to treat fecal dysfunction, therefore, throughout the description it should be understood that what is described for OAB applies equally to other forms of urinary dysfunction and fecal dysfunction. It will be appreciated however that the present invention may also be utilized for any variety of neuromodulation uses, such as fecal dysfunction, the treatment of pain or other indications, such as movement or affective disorders, as will be appreciated by one of skill in the art.
I. Neurostimulation Indications
Neurostimulation (or neuromodulation as may be used interchangeably hereunder) treatment systems, such as any of those described herein, can be used to treat a variety of ailments and associated symptoms, such as acute pain disorders, movement disorders, affective disorders, as well as bladder and bowel related dysfunction. Examples of pain disorders that may be treated by neurostimulation include failed back surgery syndrome, reflex sympathetic dystrophy or complex regional pain syndrome, causalgia, arachnoiditis, and peripheral neuropathy. Movement orders include muscle paralysis, tremor, dystonia and Parkinson's disease. Affective disorders include depressions, obsessive-compulsive disorder, cluster headache, Tourette syndrome and certain types of chronic pain. Bladder related dysfunctions include but are not limited to OAB, urge incontinence, urgency-frequency, and urinary retention. OAB can include urge incontinence and urgency-frequency alone or in combination. Urge incontinence is the involuntary loss or urine associated with a sudden, strong desire to void (urgency). Urgency-frequency is the frequent, often uncontrollable urges to urinate (urgency) that often result in voiding in very small amounts (frequency). Urinary retention is the inability to empty the bladder. Neurostimulation treatments can be configured to address a particular condition by effecting neurostimulation of targeted nerve tissues relating to the sensory and/or motor control associated with that condition or associated symptom.
In one aspect, the methods and systems described herein are particularly suited for treatment of urinary and fecal dysfunctions. These conditions have been historically under-recognized and significantly underserved by the medical community. OAB is one of the most common urinary dysfunctions. It is a complex condition characterized by the presence of bothersome urinary symptoms, including urgency, frequency, nocturia and urge incontinence. It is estimated that about 40 million Americans suffer from OAB. Of the adult population, about 16% of all men and women live with OAB symptoms.
OAB symptoms can have a significant negative impact on the psychosocial functioning and the quality of life of patients. People with OAB often restrict activities and/or develop coping strategies. Furthermore, OAB imposes a significant financial burden on individuals, their families, and healthcare organizations. The prevalence of co-morbid conditions is also significantly higher for patients with OAB than in the general population. Co-morbidities may include falls and fractures, urinary tract infections, skin infections, vulvovaginitis, cardiovascular, and central nervous system pathologies. Chronic constipation, fecal incontinence, and overlapping chronic constipation occur more frequently in patients with OAB.
Conventional treatments of OAB generally include lifestyle modifications as a first course of action. Lifestyle modifications include eliminating bladder irritants (such as caffeine) from the diet, managing fluid intake, reducing weight, stopping smoking, and managing bowel regularity. Behavioral modifications include changing voiding habits (such as bladder training and delayed voiding), training pelvic floor muscles to improve strength and control of urethral sphincter, biofeedback and techniques for urge suppression. Medications are considered a second-line treatment for OAB. These include anti-cholinergic medications (oral, transdermal patch, and gel) and oral beta-3 adrenergic agonists. However, anti-cholinergics are frequently associated with bothersome, systemic side effects including dry mouth, constipation, urinary retention, blurred vision, somnolence, and confusion. Studies have found that more than 50% of patients stop using anti-cholinergic medications within 90 days due to a lack of benefit, adverse events, or cost.
When these approaches are unsuccessful, third-line treatment options suggested by the American Urological Association include intradetrusor (bladder smooth muscle) injections of botulinum toxin (BTX), Percutaneous Tibial Nerve Stimulation (PTNS) and Sacral Nerve Stimulation (SNM). BTX is administered via a series of intradetrusor injections under cystoscopic guidance, but repeat injections of BTX are generally required every 4 to 12 months to maintain effect and BTX may undesirably result in urinary retention. A number or randomized controlled studies have shown some efficacy of BTX injections in OAB patients, but long-term safety and effectiveness of BTX for OAB is largely unknown.
PTNS therapy consists of weekly, 30-minute sessions over a period of 12 weeks, each session using electrical stimulation that is delivered from a hand-held stimulator to the sacral plexus via the tibial nerve. For patients who respond well and continue treatment, ongoing sessions, typically every 3-4 weeks, are needed to maintain symptom reduction. There is potential for declining efficacy if patients fail to adhere to the treatment schedule. Efficacy of PTNS has been demonstrated in a few randomized-controlled studies, however, there is limited data on PTNS effectiveness beyond 3-years and PTNS is not recommended for patients seeking a cure for urge urinary incontinence (UUI) (e.g., 100% reduction in incontinence episodes) (EAU Guidelines).
II. Sacral Neuromodulation
SNM is an established therapy that provides a safe, effective, reversible, and long-lasting treatment option for the management of urge incontinence, urgency-frequency, and non-obstructive urinary retention. SNM therapy involves the use of mild electrical pulses to stimulate the sacral nerves located in the lower back. Electrodes are placed next to a sacral nerve, usually at the S3 level, by inserting the electrode leads into the corresponding foramen of the sacrum. The electrodes are inserted subcutaneously and are subsequently attached to an implantable pulse generator (IPG). The safety and effectiveness of SNM for the treatment of OAB, including durability at five years for both urge incontinence and urgency-frequency patients, is supported by multiple studies and is well-documented. SNM has also been approved to treat chronic fecal incontinence in patients who have failed or are not candidates for more conservative treatments.
A. Implantation of Sacral Neuromodulation System
Currently, SNM qualification has a trial phase, and is followed if successful by a permanent implant. The trial phase is a test stimulation period where the patient is allowed to evaluate whether the therapy is effective. Typically, there are two techniques that are utilized to perform the test stimulation. The first is an office-based procedure termed the Percutaneous Nerve Evaluation (PNE) and the other is a staged trial.
In the PNE, a foramen needle is typically used first to identify the optimal stimulation location, usually at the S3 level, and to evaluate the integrity of the sacral nerves. Motor and sensory responses are used to verify correct needle placement, as described in Table 1 below. A temporary stimulation lead (a unipolar electrode) is then placed near the sacral nerve under local anesthesia. This procedure can be performed in an office setting without fluoroscopy. The temporary lead is then connected to an external pulse generator (EPG) taped onto the skin of the patient during the trial phase. The stimulation level can be adjusted to provide an optimal comfort level for the particular patient. The patient will monitor his or her voiding for 3 to 7 days to see if there is any symptom improvement. The advantage of the PNE is that it is an incision free procedure that can be performed in the physician's office using local anesthesia. The disadvantage is that the temporary lead is not securely anchored in place and has the propensity to migrate away from the nerve with physical activity and thereby cause failure of the therapy. If a patient fails this trial test, the physician may still recommend the staged trial as described below. If the PNE trial is positive, the temporary trial lead is removed and a permanent quadri-polar tined lead is implanted along with an IPG under general anesthesia. Other neuromodulation applications may have any number of electrodes and more than one lead as the therapy may require.
A staged trial involves the implantation of the permanent quadri-polar tined stimulation lead into the patient from the start. It also requires the use of a foramen needle to identify the nerve and optimal stimulation location. The lead is implanted near the S3 sacral nerve and is connected to an EPG via a lead extension. This procedure is performed under fluoroscopic guidance in an operating room and under local or general anesthesia. The EPG is adjusted to provide an optimal comfort level for the patient and the patient monitors his or her voiding for up to two weeks. If the patient obtains meaningful symptom improvement, he or she is considered a suitable candidate for permanent implantation of the IPG under general anesthesia, typically in the upper buttock area, as shown in
Table 1: Motor and Sensory Responses of SNM at Different Sacral Nerve Roots
In regard to measuring outcomes for SNM treatment of voiding dysfunction, the voiding dysfunction indications (e.g., urge incontinence, urgency-frequency, and non-obstructive urinary retention) are evaluated by unique primary voiding diary variables. The therapy outcomes are measured using these same variables. SNM therapy is considered successful if a minimum of 50% improvement occurs in any of primary voiding diary variables compared with the baseline. For urge incontinence patients, these voiding diary variables may include: number of leaking episodes per day, number of heavy leaking episodes per day, and number of pads used per day. For patients with urgency-frequency, primary voiding diary variables may include: number of voids per day, volume voided per void and degree of urgency experienced before each void. For patients with retention, primary voiding diary variables may include: catheterized volume per catheterization and number of catheterizations per day. For FI patients, the outcome measures captured by the voiding diary include: number of leaking episodes per week, number of leaking days per week, and degree of urgency experienced before each leak.
The mechanism of action of SNM is multifactorial and impacts the neuro-axis at several different levels. In patients with OAB, it is believed that pelvic and/or pudendal afferents can activate the inhibitory reflexes that promote bladder storage by inhibiting the afferent limb of an abnormal voiding reflex. This blocks input to the pontine micturition center, thereby restricting involuntary detrusor contractions without interfering with normal voiding patterns. For patients with urinary retention, SNM is believed to activate the pelvic and/or pudendal nerve afferents originating from the pelvic organs into the spinal cord. At the level of the spinal cord, these afferents may turn on voiding reflexes by suppressing exaggerated guarding reflexes, thus relieving symptoms of patients with urinary retention so normal voiding can be facilitated. In patients with fecal incontinence, it is hypothesized that SNM stimulates pelvic and/or pudendal afferent somatic fibers that inhibit colonic propulsive activity and activates the internal anal sphincter, which in turn improves the symptoms of fecal incontinence patients. The present invention relates to a system adapted to deliver neurostimulation to targeted nerve tissues in a manner that that results in partial or complete activation of the target nerve fibers, causes the augmentation or inhibition of neural activity in nerves, potentially the same or different than the stimulation target, that control the organs and structures associated with bladder and bowel function.
B. Positioning Neurostimulation Leads with EMG
While conventional sacral nerve stimulation approaches have shown efficacy in treatment of bladder and bowel related dysfunction, there exists a need to improve positioning of the neurostimulation leads and consistency between the trial and permanent implantation positions of the lead. Neurostimulation relies on consistently delivering therapeutic stimulation from a pulse generator, via one or more neurostimulation electrodes, to particular nerves or targeted regions. The neurostimulation electrodes are provided on a distal end of an implantable lead that can be advanced through a tunnel formed in patient tissue. Implantable neurostimulation systems provide patients with great freedom and mobility, but it may be easier to adjust the neurostimulation electrodes of such systems before they are surgically implanted. It is desirable for the physician to confirm that the patient has desired motor and/or sensory responses before implanting an IPG. For at least some treatments (including treatments of at least some forms of urinary and/or fecal dysfunction), demonstrating appropriate motor responses may be highly beneficial for accurate and objective lead placement while the sensory response may not be required or not available (e.g., patient is under general anesthesia).
Placement and calibration of the neurostimulation electrodes and implantable leads sufficiently close to specific nerves can be beneficial for the efficacy of treatment. Accordingly, aspects and embodiments of the present disclosure are directed to aiding and refining the accuracy and precision of neurostimulation electrode placement. Further, aspects and embodiments of the present disclosure are directed to aiding and refining protocols for setting therapeutic treatment signal parameters for a stimulation program implemented through implanted neurostimulation electrodes.
Prior to implantation of the permanent device, patients may undergo an initial testing phase to estimate potential response to treatment. As discussed above, PNE may be done under local anesthesia, using a test needle to identify the appropriate sacral nerve(s) according to a subjective sensory response by the patient. Other testing procedures can involve a two-stage surgical procedure, where a quadri-polar tined lead is implanted for a testing phase (phase 1) to determine if patients show a sufficient reduction in symptom frequency, and if appropriate, proceeding to the permanent surgical implantation of a neuromodulation device. For testing phases and permanent implantation, determining the location of lead placement can be dependent on subjective qualitative analysis by either or both of a patient or a physician.
In exemplary embodiments, determination of whether or not an implantable lead and neurostimulation electrode is located in a desired or correct location can be accomplished through use of electromyography (“EMG”), also known as surface electromyography. EMG, is a technique that uses an EMG system or module to evaluate and record electrical activity produced by muscles, producing a record called an electromyogram. EMG detects the electrical potential generated by muscle cells when those cells are electrically or neurologically activated. The signals can be analyzed to detect activation level or recruitment order. EMG can be performed through the skin surface of a patient, intramuscularly or through electrodes disposed within a patient near target muscles, or using a combination of external and internal structures. When a muscle or nerve is stimulated by an electrode, EMG can be used to determine if the related muscle is activated, (i.e. whether the muscle fully contracts, partially contracts, or does not contract) in response to the stimulus. Accordingly, the degree of activation of a muscle can indicate whether an implantable lead or neurostimulation electrode is located in the desired or correct location on a patient. Further, the degree of activation of a muscle can indicate whether a neurostimulation electrode is providing a stimulus of sufficient strength, amplitude, frequency, or duration to affect a treatment regimen on a patient. Thus, use of EMG provides an objective and quantitative means by which to standardize placement of implantable leads and neurostimulation electrodes, reducing the subjective assessment of patient sensory responses.
In some approaches, positional titration procedures may optionally be based in part on a paresthesia or pain-based subjective response from a patient. In contrast, EMG triggers a measureable and discrete muscular reaction. As the efficacy of treatment often relies on precise placement of the neurostimulation electrodes at target tissue locations and the consistent, repeatable delivery of neurostimulation therapy, using an objective EMG measurement can substantially improve the utility and success of SNM treatment. The measureable muscular reaction can be a partial or a complete muscular contraction, including a response below the triggering of an observable motor response, such as those shown in Table 1, depending on the stimulation of the target muscle. In addition, by utilizing a trial system that allows the neurostimulation lead to remain implanted for use in the permanently implanted system, the efficacy and outcome of the permanently implanted system is more consistent with the results of the trial period, which moreover leads to improved patient outcomes. Moreover, the capability of the EMG systems described herein to quantitatively sense partial contraction can facilitate the use of positioning and/or programming stimulation levels below those appropriate for reliable subjective assessment by the patient. Hence, pain associated with electrode positioning and/or programming may optionally be reduced or eliminated by the use of sub-subjective EMG stimulation signals, with the programming and/or positioning of some embodiments relying substantially, largely, primarily, or even entirely on sub-subjective stimulation signals.
C. Example Neurostimulation Systems
In one aspect, the clinician programmer 60 is used by a physician to adjust the settings of the EPG and/or IPG while the lead is implanted within the patient. The clinician programmer can be a tablet computer used by the clinician to program the IPG, or to control the EPG during the trial period. The clinician programmer can also include capability to record stimulation-induced electromyograms to facilitate lead placement and programming. The patient remote 70 can allow the patient to turn the stimulation on or off, or to vary stimulation from the IPG while implanted, or from the EPG during the trial phase.
In another aspect, the clinician programmer 60 has a control unit which can include a microprocessor and specialized computer-code instructions for implementing methods and systems for use by a physician in deploying the treatment system and setting up treatment parameters. The clinician programmer generally includes a user interface which can be a graphical user interface, an EMG module, electrical contacts such as an EMG input that can couple to an EMG output stimulation cable, an EMG stimulation signal generator, and a stimulation power source. The stimulation cable can further be configured to couple to any or all of an access device (e.g., a foramen needle), a treatment lead of the system, or the like. The EMG input may be configured to be coupled with one or more sensory patch electrode(s) for attachment to the skin of the patient adjacent a muscle (e.g., a muscle enervated by a target nerve). Other connectors of the clinician programmer may be configured for coupling with an electrical ground or ground patch, an electrical pulse generator (e.g., an EPG or an IPG), or the like. As noted above, the clinician programmer can include a module with hardware and computer-code to execute EMG analysis, where the module can be a component of the control unit microprocessor, a pre-processing unit coupled to or in-line with the stimulation and/or sensory cables, or the like.
In some aspects, the clinician programmer is configured to operate in combination with an EPG when placing leads in a patient body. The clinician programmer can be electronically coupled to the EPG wirelessly during test simulation or through a specialized cable set, and . and allow the clinician programmer to configure, modify, or otherwise program the electrodes on the leads connected to the EPG.
The electrical pulses generated by the EPG and IPG are delivered to one or more targeted nerves via one or more neurostimulation electrodes at or near a distal end of each of one or more leads. The leads can have a variety of shapes, can be a variety of sizes, and can be made from a variety of materials, which size, shape, and materials can be tailored to the specific treatment application. While in this embodiment, the lead is of a suitable size and length to extend from the IPG and through one of the foramen of the sacrum to a targeted sacral nerve, in various other applications, the leads may be, for example, implanted in a peripheral portion of the patient's body, such as in the arms or legs, and can be configured to deliver electrical pulses to the peripheral nerve such as may be used to relieve chronic pain. It is appreciated that the leads and/or the stimulation programs may vary according to the nerves being targeted.
Properties of the electrical pulses can be controlled via a controller of the implanted pulse generator. In some embodiments, these properties can include, for example, the frequency, amplitude, pattern, duration, or other aspects of the electrical pulses. These properties can include, for example, a voltage, a current, or the like. This control of the electrical pulses can include the creation of one or more electrical pulse programs, plans, or patterns, and in some embodiments, this can include the selection of one or more pre-existing electrical pulse programs, plans, or patterns. In the embodiment depicted in
In some embodiments, the trial neurostimulation system utilizes an EPG 80 within an EPG patch 81 that is adhered to the skin of a patient and is coupled to the implanted neurostimulation lead 20 through a lead extension 22, which is coupled with the lead 20 through a connector 21. This extension and connector structure allows the lead to be extended so that the EPG patch can be placed on the abdomen and allows use of a lead having a length suitable for permanent implantation should the trial prove successful. This approach may utilize two percutaneous incisions, the connector provided in the first incision and the lead extensions extending through the second percutaneous incision, there being a short tunneling distance (e.g., about 10 cm) there between. This technique may also minimize movement of an implanted lead during conversion of the trial system to a permanently implanted system.
In one aspect, the EPG unit is wirelessly controlled by a patient remote and/or the clinician programmer in a similar or identical manner as the IPG of a permanently implanted system. The physician or patient may alter treatment provided by the EPG through use of such portable remotes or programmers and the treatments delivered are recorded on a memory of the programmer for use in determining a treatment suitable for use in a permanently implanted system. The clinician programmer can be used in lead placement, programming and/or stimulation control in each of the trial and permanent nerve stimulation systems. In addition, each nerve stimulation system allows the patient to control stimulation or monitor battery status with the patient remote. This configuration is advantageous as it allows for an almost seamless transition between the trial system and the permanent system. From the patient's viewpoint, the systems will operate in the same manner and be controlled in the same manner, such that the patient's subjective experience in using the trial system more closely matches what would be experienced in using the permanently implanted system. Thus, this configuration reduces any uncertainties the patient may have as to how the system will operate and be controlled such that the patient will be more likely to convert a trial system to a permanent system.
As shown in the detailed view of
In one aspect, the IPG is rechargeable wirelessly through conductive coupling by use of a charging device 50 (CD), which is a portable device powered by a rechargeable battery to allow patient mobility while charging. The CD is used for transcutaneous charging of the IPG through RF induction. The CD can either be patched to the patient's skin with an affixation device, such as an adhesive carrier 1 or a belt 9. The CD may be charged by plugging the CD directly into an outlet or by placing the CD in a charging dock or station 55 that connects to an AC wall outlet or other power source.
The system may further include a patient remote 70 and clinician programmer 60, each configured to wirelessly communicate with the implanted IPG, or with the EPG during a trial, as shown in the schematic of the nerve stimulation system in
One or more properties of the electrical pulses can be controlled via a controller of the IPG or EPG. In some embodiments, these properties can include, for example, the frequency, strength, pattern, duration, or other aspects of the timing and magnitude of the electrical pulses. These properties can further include, for example, a voltage, a current, or the like. This control of the electrical pulses can include the creation of one or more electrical pulse programs, plans, or patterns, and in some embodiments, this can include the selection of one or more pre-existing electrical pulse programs, plans, or patterns. In one aspect, the IPG 10 includes a controller having one or more pulse programs, plans, or patterns that may be created and/or pre-programmed. In some embodiments, the IPG can be programmed to vary stimulation parameters including pulse amplitude in a range from 0 mA to 10 mA, pulse width in a range from 50 μs to 500 μs, pulse frequency in a range from 5 Hz to 250 Hz, stimulation modes (e.g., continuous or cycling), and electrode configuration (e.g., anode, cathode, or off), to achieve the optimal therapeutic outcome specific to the patient. In particular, this allows for an optimal setting to be determined for each patient even though each parameter may vary from person to person.
As shown in
In some embodiments, such as that shown in
In one aspect, utilization of ceramic material provides an efficient, radio-frequency-transparent window for wireless communication with the external patient remote and clinician's programmer as the communication antenna is housed inside the hermetic ceramic case. This ceramic window has further facilitated miniaturization of the implant while maintaining an efficient, radio-frequency-transparent window for long term and reliable wireless communication between the IPG and external controllers, such as the patient remote and clinician programmer. The IPG's wireless communication is generally stable over the lifetime of the device, unlike prior art products where the communication antenna is placed in the header outside the hermetic case. The communication reliability of such prior art devices tends to degrade due to the change in dielectric constant of the header material in the human body over time.
In another aspect, the ferrite core is part of the charging coil assembly 15, shown in
In order to confirm correct lead placement, it is desirable for the physician to confirm that the patient has both adequate motor and sensory responses before transitioning the patient into the staged trial phase or implanting the permanent IPG. However, sensory response is a subjective evaluation and may not always be available, such as when the patient is under general anesthesia. Experiments have shown that demonstrating appropriate motor responses is advantageous for accurate placement, even if sensory responses are available. As discussed above, EMG is a tool which records electrical activity of skeletal muscles. This sensing feature provides an objective criterion for the clinician to determine if the sacral nerve stimulation results in adequate motor response rather than relying solely on subjective sensory criteria. EMG can be used not only to verify optimal lead position during lead placement, but also to provide a standardized and more accurate approach to determine electrode thresholds, which in turn provides quantitative information supporting electrode selection for programming. Using EMG to verify activation of motor responses can further improve the lead placement performance of less experienced operators and allow such physicians to perform lead placement with confidence and greater accuracy.
In one aspect, the system is configured to have EMG sensing capability during re-programming, which can be particularly valuable. Stimulation levels during re-programming are typically low to avoid patient discomfort which often results in difficult generation of motor responses. Involuntary muscle movement while the patient is awake may also cause noise that is difficult for the physician to differentiate. In contrast to conventional approaches, EMG allows the clinician to detect motor responses at very low stimulation levels (e.g., sub-threshold), and help them distinguish a motor response originated by sacral nerve stimulation from involuntary muscle movement.
Referring to
III. Charging of Fully Implanted Neurostimulation Systems
In one aspect, a neurostimulation system in accordance with the present invention is fully implantable and powered with a rechargeable battery that allows the system to provide therapy over the lifetime of the device with only periodic transcutaneous charging by an external CD. This feature increases the useful life of the neurostimulation system as compared to conventional neurostimulation systems that utilize a non-rechargeable batteries which must be surgically removed and replaced every three to four years. This conventional approach to fully implanted neurostimulation systems clearly results in significant discomfort and inconvenience for the patient. In addition, many patients may be reluctant to receive a therapy that requires periodic surgical intervention every few years. In contrast, a neurostimulation system utilizing transcutaneous charging in accordance with the principles described herein allows such a system to function for 10 years or more without invasive interventions to replace a battery, thereby improving patient comfort and acceptance of implanted neurostimulation therapies.
In one aspect, the systems and methods provide transcutaneous charging of implanted devices by wireless charging that uses an electromagnetic field to transfer energy between two objects. This approach uses a charging station or device that sends energy through a magnetic or inductive coupling to an energy receiving unit of the implanted device, which then uses that energy to charge a battery in the implanted device. Such charging methods typically use an external device with a charging coil that creates an alternating electromagnetic field from within the charging unit, and a second coil in the implanted device in which an electromagnetic field is induced, which the implanted device then converts back into electrical current to charge the battery. The coils must generally be in close proximity to form an electrical transformer and maintained in close proximity for a duration of time sufficient to fully charge the battery. In many conventional devices, the coil configurations are such that the coils must be placed in close proximity, typically less than a few centimeters. While wireless charging at greater distances can be achieved through various other approaches, such as resonant inductive coupling, these approaches may require precise alignment between coils, while other approaches may require coils of increased size and/or high powered charging. Wireless charging can be further understood by reference to U.S. Pat. No. 6,972,543, entitled “Series resonant inductive charging circuit,” which is incorporated herein by reference for all purposes.
The above noted aspects of wireless charging present substantial challenges to charging of implanted medical devices, since it is desirable for such devices to be of reduced size and weight, as well as to minimize exposure of the patient to high-powered charging stations. These aspects of wireless charging are particularly challenging in terms of implanted neurostimulation devices, which are typically implanted at a greater depths, such as a depth of about 3 cm, beneath a thin layer of muscle and/or fatty tissues in a lower back of the patient, where the patient cannot readily access or observe the placement and/or alignment of an external charging device. Given these challenges associated with wireless charging of implanted neurostimulation devices, conventional neurostimulation devices have utilized non-rechargeable batteries with life-times of about three to four years. While this approach avoids the above noted drawbacks, it is also subjects the patients to periodic invasive surgical procedures every time the battery needs to be replaced.
In one aspect, the system and charging methods of the present invention overcome these challenges associated with wireless charging due in part to the unique construction of the wireless receiving unit of the neurostimulation device and external CD, and also by use of certain features that improve positioning and alignment of the external CD with the implanted device to allow for more robust, consistent charging of the implanted device. In addition, the features described herein allow a patient to achieve that precise positioning and alignment with relative ease, without the aid of a caretaker or medical personnel. Furthermore, the above objectives are provided while still allowing for an implanted neurostimulation device of reduced size and weight and while maintaining patient mobility by use of a portable external charging device that remains attached to the patient during charging.
In one aspect, the systems and methods described herein allow for transcutaneous charging of a fully implanted neurostimulation device by a portable external charging device adhered to the patient with an affixation device for a duration of time, typically less than a few hours, such as within two hours or less. In one aspect, the attachment device is adapted to allow placement of the external CD by the patient in a position and/or alignment suitable for wireless charging and to maintain that position and/or alignment for the duration of charging. Examples of such attachment devices are shown in
A. Implant Battery Charging Protocol
In some embodiments, the IPG of the neurostimulation system includes a charging coil adapted to capture energy necessary to recharge the internal battery. The battery voltage is measured through an Analog to Digital (A/D) converter of the IPG and is also monitored by the battery monitor during charging. The battery monitor compares the battery voltage with a voltage reference. Based on the battery monitor outputs, the current charger inside the implant is controlled accordingly. When the battery voltage is above 3.0V, it is in the normal charging mode. The charging current is set to the default value of ˜25 mA (C/2). Charging will stop when the battery voltage reaches 4.05V to prevent over-charge. To charge up a battery with battery voltage between 2.5V and 3.0V, a smaller charging current (˜2.5V) will be used until it reaches 3.0V where the battery goes into the normal charging mode. In some embodiments, the IPG charging circuitry is designed in a such way that no recharging is possible when the battery voltage is below 2.5V, to avoid potential thermal runaway causing rapid temperature increase of the battery, which is unlikely though due to the low capacity of the over-discharged battery. Field testing has demonstrated that such a battery can be safely recharged from a very low voltage state (0.1V). The battery voltage dropping below 2.5V is a very rare occurrence, because the IPG will be forced into a hibernation mode when the battery voltage drops below 3.0V during which the battery could only be drained by a tiny leakage current such that it would take more than one year for the battery voltage to drop below 2.5V from 3.0V. In some embodiments, the capacity of the implant battery is 50 mAh such that at nominal stimulation settings for OAB, the IPG lasts approximately two weeks before needing recharge.
In some embodiments, the external CD is a mobile puck-shaped device that is configured to provide wireless and transcutaneous recharging of the implanted IPG while maintained at a suitable position and/or alignment on the patient. The CD includes a microcontroller which handles control of charging and communication with the IPG. The CD also includes a battery, which can be recharged in a charging station or by coupling directly to a power source, which allows for charging while the patient is mobile. The CD is shaped and dimensioned to fit comfortably in a hand of the patient to facilitate placement of the CD on the patient for recharging, as well as to allow ready handling of the CD by the patient. In some embodiments, the CD includes a temperature sensor to ensure that the charger will never overheat. The charger monitors the battery charging status and automatically shuts itself off when the implant battery is fully charged.
In one aspect, the CD is a portable device having an enlarged upper portion and a protruding circular portion on a underside thereof. The enlarged upper portion, which typically includes the rechargeable battery and associated electronics and microcontroller, is dimensioned so as to be easily held by a user to facilitate handling and positioning of the CD by the patient. The protruding circular portion that houses the charging coil and includes a substantially planar surface for engaging the skin of the patient over the implanted IPG. While the CD is depicted as a puck-shaped device it is appreciated that the CD can be defined in various other shapes while still providing certain features of the various aspects described herein.
The CD may be charged by multiple options, such as those in
In some embodiments, to get the recharging started, the patient needs to move the CD over the implanted IPG. The CD provides audio feedback to assist the patient in finding the IPG. An audio transducer audibly indicates when the IPG is near the charging coil to the IPG. The CD emits three short beeps when the CD is close to the IPG (enough to be detectable) yet not within the charging zone, and a long beep to indicate the CD is in the IPG charging zone.
Optionally, a patient will then rotate the CD to achieve better angular alignment. A haptic feedback is provided when optimal angular alignment is achieved between the CD and IPG. An audio tone signals that the IPG is now being charged by the CD. In addition, a periodic green flashing light on the CD indicates the charging is currently on-going. If optimal alignment is not achieved within 15 seconds, but the charging field is strong enough to charge the implant battery, the charging process will continue, and the audio will turn off If the charger moves during charging and charging field is lost completely, the CD will emit 3 short beeps while in range yet not in the IPG charging zone. This alerts the user that the CD is off target and needs to be re-located over the IPG. When charging is complete, the CD provides a user indication that charging is complete and powers off. For example, the CD can output a unique series of audio tones (e.g. three short beeps) that indicate the end of charging and the flashing green light will be off. In some embodiments, a watchdog timer is used to verify that the microcontroller is operational. In the event of program malfunction, the microcontroller will enter a safe state that either powers down the coil or turns off the coil drive.
By utilizing the devices and charging methods described herein, the IPG can be recharged at greater depths, such as about 3 cm. Having a deep charging depth allows for improved patient comfort during charging as it allows the implant to be placed in a desirable location within tissues while still allowing for transcutaneous wireless charging with a portable CD. To efficiently recharge the described, however, a precise position and/or alignment of the CD must be achieved and reasonably maintained for a duration of time sufficient to complete charging of the IPG battery. This can be accomplished by use of various affixation methods and devices adapted for use with the CD, such as those shown and described below.
B. Example Affixation Devices
In one aspect, the carrier device includes a frame releasably coupleable with the CD and having multiple outwardly extending tabs with a pressure sensitive adhesive suitable for adhesively securing the CD to the skin of the patient. The frame is configured to allow the CD to contact a skin of the patient directly over the implanted IPG so as to minimize distance between the CD and implanted IPG.
In another aspect, the carrier 1 includes a mounting interface 4 by which the CD 50 is releasably coupled with the carrier 1. In some embodiments, the mounting interface 4 engages a corresponding mounting feature 54 of the CD 50 so as to securely couple the CD 50 within the carrier 1 while still allowing rotation of the CD 50 relative the charging device. In this example, the mounting interface 4 is a lip or ridge and the corresponding mounting feature 54 is a groove extending about the circular protruding portion 53. The CD 50 is releasably coupled with the carrier 1 in preparation for charging by inserting the circular protruding portion 53 through the mounting hole 3 until the lip 4 is fittingly received within a corresponding groove 54. It is appreciated that since carrier couples with CD along the mounting interface disposed about the circular protruding portion that such a carrier could be used with a CD having an upper housing designed in various other shapes, for example the CD in
In one aspect, the carrier includes one or more tabs are formed of a material sufficiently stiff to maintain the first position and the second position when static, yet sufficiently flexible to bend slightly so as to conform to the skin of the patient when in the second position so as to maintain the CD 50 mounted in the carrier 1 against the patient's skin for the duration of charging.
In one aspect, the carrier includes a spring-type mechanism or feature that facilitate ready deployment of the multiple adhesive tabs into engagement with a skin of the patient when the charger device is in a suitable position for charging, as may be indicated by an audible and/or haptic signal from the charging device. Such a configuration is advantageous in a sacral neuromodulation system in which the IPG is implanted in a lower back region and the patient is positioning the charging device in the lower back region with a single hand. In response, to an audible and/or haptic signal output from the charging device that indicates a suitable position for charging, the patient can effect deployment of multiple adhesive tabs by the spring-type mechanism or feature of the charging device carrier. This action can be effected by a pressing against the carrier with a finger of the single hand, for example by depressing a button or lever of the carrier or by pressing against a single tab. In some embodiments, the spring-type feature is provided by the design of the carrier frame itself. The carrier frame can comprise a semi-rigid or rigid material having a standard configuration and an inverted configuration, the frame resiliently springing toward the standard configuration from the inverted configuration.
In one such embodiment, the carrier 1 comprises a frame configured with a standard configuration, in which the tabs 5 are in the second position, and an inverted configuration, in which the tabs 5 are in the first position. Applying a slight force to one or more tabs in the first position in a direction of the arrow shown in
As shown in
Once the CD is properly positioned and affixed to the skin of the patient, the patient can then adjust the rotational alignment of the CD. In one aspect, the carrier is configured such that the CD can be manually rotated while mounted within, yet sufficiently secured such that the CD does not rotate when the CD is static, that is, when no moment forced are applied to the CD. This may be accomplished by providing a mounting interface that allows rotation but provides enough friction to prevent undesired rotation when the device is not being manually rotated by the patient. As shown in
In the foregoing specification, the invention is described with reference to specific embodiments thereof, but those skilled in the art will recognize that the invention is not limited thereto. Various features and aspects of the above-described invention can be used individually or jointly. Further, the invention can be utilized in any number of environments and applications beyond those described herein without departing from the broader spirit and scope of the specification. The specification and drawings are, accordingly, to be regarded as illustrative rather than restrictive. It will be recognized that the terms “comprising,” “including,” and “having,” as used herein, are specifically intended to be read as open-ended terms of art.
This application is a divisional of U.S. application Ser. No. 14/992,977, filed on Jan. 11, 2016 (now U.S. Patent No. 10,682,521 issued Jun. 16, 2020), which claims the benefit of priority of U.S. Provisional Application No. 62/101,884, filed on Jan. 9, 2015, the entire contents of which are incorporated herein by reference. The present application is related to U.S. Provisional Patent Application Nos. 62/038,122 filed on Aug. 15, 2014, entitled “Devices and Methods for Anchoring of Neurostimulation Leads”; 62/038,131 filed on Aug. 15, 2014, entitled “External Pulse Generator Device and Associated Methods for Trial Nerve Stimulation”; 62/041,611 filed on Aug. 25, 2014, entitled “Electromyographic Lead Positioning and Stimulation Titration in a Nerve Stimulation System for Treatment of Overactive Bladder, Pain and Other Indicators”; and concurrently filed U.S. Provisional Patent Application Nos. 62/101,888, entitled “Electromyographic Lead Positioning and Stimulation Titration in a Nerve Stimulation System for Treatment of Overactive Bladder”; 62/101,888, entitled “Integrated Electromyographic Clinician Programmer For Use With an Implantable Neurostimulator”; 62/101,897, entitled “Systems and Methods for Neurostimulation Electrode Configurations Based on Neural Localization”; 62/101,666, entitled “Patient Remote and Associated Methods of Use With a Nerve Stimulation System”; and 62/101,782, entitled “Improved Antenna and Methods of Use For an Implantable Nerve Stimulator,” all filed on Jan. 9, 2015, each of which is assigned to the same assignee as the present application, and incorporated herein by reference in its entirety for all purposes.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3057356 | Greatbatch | Oct 1962 | A |
| 3348548 | Chardack | Oct 1967 | A |
| 3646940 | Timm et al. | Mar 1972 | A |
| 3824129 | Fagan, Jr. | Jul 1974 | A |
| 3825015 | Berkovits | Jul 1974 | A |
| 3888260 | Fischell | Jun 1975 | A |
| 3902501 | Citron et al. | Sep 1975 | A |
| 3939843 | Smyth | Feb 1976 | A |
| 3942535 | Schulman | Mar 1976 | A |
| 3970912 | Hoffman | Jul 1976 | A |
| 3995623 | Blake et al. | Dec 1976 | A |
| 4019518 | Maurer et al. | Apr 1977 | A |
| 4044774 | Corbin et al. | Aug 1977 | A |
| 4082097 | Mann et al. | Apr 1978 | A |
| 4141365 | Fischell et al. | Feb 1979 | A |
| 4166469 | Littleford | Sep 1979 | A |
| 4269198 | Stokes | May 1981 | A |
| 4285347 | Hess | Aug 1981 | A |
| 4340062 | Thompson et al. | Jul 1982 | A |
| 4379462 | Borkan et al. | Apr 1983 | A |
| 4407303 | Akerstrom | Oct 1983 | A |
| 4437475 | White | Mar 1984 | A |
| 4512351 | Pohndorf | Apr 1985 | A |
| 4550731 | Batina et al. | Nov 1985 | A |
| 4558702 | Barreras et al. | Dec 1985 | A |
| 4654880 | Sontag | Mar 1987 | A |
| 4662382 | Sluetz et al. | May 1987 | A |
| 4719919 | Marchosky et al. | Jan 1988 | A |
| 4721118 | Harris | Jan 1988 | A |
| 4722353 | Sluetz | Feb 1988 | A |
| 4744371 | Harris | May 1988 | A |
| 4800898 | Hess et al. | Jan 1989 | A |
| 4848352 | Pohndorf et al. | Jul 1989 | A |
| 4860446 | Lessar et al. | Aug 1989 | A |
| 4957118 | Erlebacher | Sep 1990 | A |
| 4989617 | Memberg et al. | Feb 1991 | A |
| 5012176 | Laforge | Apr 1991 | A |
| 5052407 | Hauser et al. | Oct 1991 | A |
| 5197466 | Marchosky et al. | Mar 1993 | A |
| 5204611 | Nor et al. | Apr 1993 | A |
| 5255691 | Otten | Oct 1993 | A |
| 5257634 | Kroll | Nov 1993 | A |
| 5342408 | Decoriolis et al. | Aug 1994 | A |
| 5394877 | Orr | Mar 1995 | A |
| 5439485 | Mar et al. | Aug 1995 | A |
| 5476499 | Hirschberg | Dec 1995 | A |
| 5484445 | Knuth | Jan 1996 | A |
| 5571148 | Loeb et al. | Nov 1996 | A |
| 5592070 | Mino | Jan 1997 | A |
| 5637981 | Nagai et al. | Jun 1997 | A |
| 5676162 | Larson, Jr. et al. | Oct 1997 | A |
| 5690693 | Wang et al. | Nov 1997 | A |
| 5702428 | Tippey et al. | Dec 1997 | A |
| 5702431 | Wang et al. | Dec 1997 | A |
| 5712795 | Layman et al. | Jan 1998 | A |
| 5713939 | Nedungadi et al. | Feb 1998 | A |
| 5733313 | Barreras, Sr. et al. | Mar 1998 | A |
| 5735887 | Barreras, Sr. et al. | Apr 1998 | A |
| 5741316 | Chen et al. | Apr 1998 | A |
| 5871532 | Schroeppel | Feb 1999 | A |
| 5876423 | Braun | Mar 1999 | A |
| 5902331 | Bonner et al. | May 1999 | A |
| 5948006 | Mann | Sep 1999 | A |
| 5949632 | Barreras, Sr. et al. | Sep 1999 | A |
| 5957965 | Moumane et al. | Sep 1999 | A |
| 5991665 | Wang et al. | Nov 1999 | A |
| 6027456 | Feler et al. | Feb 2000 | A |
| 6035237 | Schulman et al. | Mar 2000 | A |
| 6052624 | Mann | Apr 2000 | A |
| 6055456 | Gerber | Apr 2000 | A |
| 6057513 | Ushikoshi et al. | May 2000 | A |
| 6067474 | Schulman et al. | May 2000 | A |
| 6075339 | Reipur et al. | Jun 2000 | A |
| 6076017 | Taylor et al. | Jun 2000 | A |
| 6081097 | Seri et al. | Jun 2000 | A |
| 6083247 | Rutten et al. | Jul 2000 | A |
| 6104957 | Alo et al. | Aug 2000 | A |
| 6104960 | Duysens et al. | Aug 2000 | A |
| 6138681 | Chen et al. | Oct 2000 | A |
| 6165180 | Cigaina et al. | Dec 2000 | A |
| 6166518 | Echarri et al. | Dec 2000 | A |
| 6169387 | Kaib | Jan 2001 | B1 |
| 6172556 | Prentice | Jan 2001 | B1 |
| 6178353 | Griffith et al. | Jan 2001 | B1 |
| 6181105 | Cutolo et al. | Jan 2001 | B1 |
| 6191365 | Avellanet | Feb 2001 | B1 |
| 6208894 | Schulman et al. | Mar 2001 | B1 |
| 6212430 | Kung | Apr 2001 | B1 |
| 6212431 | Hahn et al. | Apr 2001 | B1 |
| 6221513 | Lasater | Apr 2001 | B1 |
| 6227204 | Baumann et al. | May 2001 | B1 |
| 6243608 | Pauly et al. | Jun 2001 | B1 |
| 6246911 | Seligman | Jun 2001 | B1 |
| 6249703 | Stanton et al. | Jun 2001 | B1 |
| 6265789 | Honda et al. | Jul 2001 | B1 |
| 6275737 | Mann | Aug 2001 | B1 |
| 6278258 | Echarri et al. | Aug 2001 | B1 |
| 6305381 | Weijand et al. | Oct 2001 | B1 |
| 6306100 | Prass | Oct 2001 | B1 |
| 6315721 | Schulman et al. | Nov 2001 | B2 |
| 6316909 | Honda et al. | Nov 2001 | B1 |
| 6321118 | Hahn | Nov 2001 | B1 |
| 6327504 | Dolgin et al. | Dec 2001 | B1 |
| 6354991 | Gross et al. | Mar 2002 | B1 |
| 6360750 | Gerber et al. | Mar 2002 | B1 |
| 6381496 | Meadows et al. | Apr 2002 | B1 |
| 6393325 | Mann et al. | May 2002 | B1 |
| 6438423 | Rezai et al. | Aug 2002 | B1 |
| 6442434 | Zarinetchi et al. | Aug 2002 | B1 |
| 6453198 | Torgerson et al. | Sep 2002 | B1 |
| 6466817 | Kaula et al. | Oct 2002 | B1 |
| 6473652 | Sarwal et al. | Oct 2002 | B1 |
| 6500141 | Irion et al. | Dec 2002 | B1 |
| 6505075 | Weiner | Jan 2003 | B1 |
| 6505077 | Kast et al. | Jan 2003 | B1 |
| 6510347 | Borkan | Jan 2003 | B2 |
| 6516227 | Meadows et al. | Feb 2003 | B1 |
| 6517227 | Stidham et al. | Feb 2003 | B2 |
| 6542846 | Miller et al. | Apr 2003 | B1 |
| 6553263 | Meadows et al. | Apr 2003 | B1 |
| 6584355 | Stessman | Jun 2003 | B2 |
| 6600954 | Cohen et al. | Jul 2003 | B2 |
| 6609031 | Law et al. | Aug 2003 | B1 |
| 6609032 | Woods et al. | Aug 2003 | B1 |
| 6609945 | Jimenez et al. | Aug 2003 | B2 |
| 6652449 | Gross et al. | Nov 2003 | B1 |
| 6662051 | Eraker et al. | Dec 2003 | B1 |
| 6664763 | Echarri et al. | Dec 2003 | B2 |
| 6685638 | Taylor et al. | Feb 2004 | B1 |
| 6721603 | Zabara et al. | Apr 2004 | B2 |
| 6735474 | Loeb et al. | May 2004 | B1 |
| 6745077 | Griffith et al. | Jun 2004 | B1 |
| 6809701 | Amundson et al. | Oct 2004 | B2 |
| 6836684 | Rijkhoff et al. | Dec 2004 | B1 |
| 6847849 | Mamo et al. | Jan 2005 | B2 |
| 6892098 | Ayal et al. | May 2005 | B2 |
| 6895280 | Meadows et al. | May 2005 | B2 |
| 6896651 | Gross et al. | May 2005 | B2 |
| 6901287 | Davis et al. | May 2005 | B2 |
| 6941171 | Mann et al. | Sep 2005 | B2 |
| 6971393 | Mamo et al. | Dec 2005 | B1 |
| 6972543 | Wells et al. | Dec 2005 | B1 |
| 6989200 | Byers et al. | Jan 2006 | B2 |
| 6990376 | Tanagho et al. | Jan 2006 | B2 |
| 6999819 | Swoyer et al. | Feb 2006 | B2 |
| 7051419 | Schrom et al. | May 2006 | B2 |
| 7054689 | Whitehurst et al. | May 2006 | B1 |
| 7069081 | Biggs et al. | Jun 2006 | B2 |
| 7127298 | He et al. | Oct 2006 | B1 |
| 7131996 | Wasserman et al. | Nov 2006 | B2 |
| 7142925 | Bhadra et al. | Nov 2006 | B1 |
| 7146219 | Sieracki et al. | Dec 2006 | B2 |
| 7151914 | Brewer | Dec 2006 | B2 |
| 7167749 | Biggs et al. | Jan 2007 | B2 |
| 7167756 | Torgerson et al. | Jan 2007 | B1 |
| 7177690 | Woods et al. | Feb 2007 | B2 |
| 7177698 | Klosterman et al. | Feb 2007 | B2 |
| 7181286 | Sieracki et al. | Feb 2007 | B2 |
| 7184836 | Meadows et al. | Feb 2007 | B1 |
| 7187978 | Malek et al. | Mar 2007 | B2 |
| 7191005 | Stessman | Mar 2007 | B2 |
| 7212110 | Martin et al. | May 2007 | B1 |
| 7225028 | Della Santina et al. | May 2007 | B2 |
| 7225032 | Schmeling et al. | May 2007 | B2 |
| 7231254 | DiLorenzo | Jun 2007 | B2 |
| 7234853 | Givoletti | Jun 2007 | B2 |
| 7239918 | Strother et al. | Jul 2007 | B2 |
| 7245972 | Davis | Jul 2007 | B2 |
| 7286880 | Olson et al. | Oct 2007 | B2 |
| 7295878 | Meadows et al. | Nov 2007 | B1 |
| 7305268 | Gliner et al. | Dec 2007 | B2 |
| 7317948 | King et al. | Jan 2008 | B1 |
| 7324852 | Barolat et al. | Jan 2008 | B2 |
| 7324853 | Ayal et al. | Jan 2008 | B2 |
| 7326181 | Katims | Feb 2008 | B2 |
| 7328068 | Spinelli et al. | Feb 2008 | B2 |
| 7330764 | Swoyer et al. | Feb 2008 | B2 |
| 7359751 | Erickson et al. | Apr 2008 | B1 |
| 7369894 | Gerber | May 2008 | B2 |
| 7386348 | North et al. | Jun 2008 | B2 |
| 7387603 | Gross et al. | Jun 2008 | B2 |
| 7396265 | Darley et al. | Jul 2008 | B2 |
| 7415308 | Gerber et al. | Aug 2008 | B2 |
| 7444181 | Shi et al. | Oct 2008 | B2 |
| 7444184 | Boveja et al. | Oct 2008 | B2 |
| 7450991 | Smith et al. | Nov 2008 | B2 |
| 7460911 | Cosendai et al. | Dec 2008 | B2 |
| 7463928 | Lee et al. | Dec 2008 | B2 |
| 7470236 | Kelleher et al. | Dec 2008 | B1 |
| 7483752 | Von Arx et al. | Jan 2009 | B2 |
| 7486048 | Tsukamoto et al. | Feb 2009 | B2 |
| 7496404 | Meadows et al. | Feb 2009 | B2 |
| 7515967 | Phillips et al. | Apr 2009 | B2 |
| 7532936 | Erickson et al. | May 2009 | B2 |
| 7539538 | Parramon et al. | May 2009 | B2 |
| 7551960 | Forsberg et al. | Jun 2009 | B2 |
| 7555346 | Woods et al. | Jun 2009 | B1 |
| 7565203 | Greenberg et al. | Jul 2009 | B2 |
| 7574262 | Haugland et al. | Aug 2009 | B2 |
| 7578819 | Bleich et al. | Aug 2009 | B2 |
| 7580752 | Gerber et al. | Aug 2009 | B2 |
| 7582053 | Gross et al. | Sep 2009 | B2 |
| 7617002 | Goetz | Nov 2009 | B2 |
| 7640059 | Forsberg et al. | Dec 2009 | B2 |
| 7643880 | Tanagho et al. | Jan 2010 | B2 |
| 7650192 | Wahlstrand | Jan 2010 | B2 |
| 7706889 | Gerber et al. | Apr 2010 | B2 |
| 7720547 | Denker et al. | May 2010 | B2 |
| 7725191 | Greenberg et al. | May 2010 | B2 |
| 7734355 | Cohen et al. | Jun 2010 | B2 |
| 7738963 | Hickman et al. | Jun 2010 | B2 |
| 7738965 | Phillips et al. | Jun 2010 | B2 |
| 7747330 | Nolan et al. | Jun 2010 | B2 |
| 7771838 | He et al. | Aug 2010 | B1 |
| 7774069 | Olson et al. | Aug 2010 | B2 |
| 7801619 | Gerber et al. | Sep 2010 | B2 |
| 7813803 | Heruth et al. | Oct 2010 | B2 |
| 7813809 | Strother et al. | Oct 2010 | B2 |
| 7826901 | Lee et al. | Nov 2010 | B2 |
| 7848818 | Barolat et al. | Dec 2010 | B2 |
| 7878207 | Goetz et al. | Feb 2011 | B2 |
| 7904167 | Klosterman et al. | Mar 2011 | B2 |
| 7912555 | Swoyer et al. | Mar 2011 | B2 |
| 7925357 | Phillips et al. | Apr 2011 | B2 |
| 7932696 | Peterson | Apr 2011 | B2 |
| 7933656 | Sieracki et al. | Apr 2011 | B2 |
| 7935051 | Miles et al. | May 2011 | B2 |
| 7937158 | Erickson et al. | May 2011 | B2 |
| 7952349 | Huang et al. | May 2011 | B2 |
| 7957818 | Swoyer | Jun 2011 | B2 |
| 7979119 | Kothandaraman et al. | Jul 2011 | B2 |
| 7979126 | Payne et al. | Jul 2011 | B2 |
| 7988507 | Darley et al. | Aug 2011 | B2 |
| 8000782 | Gharib et al. | Aug 2011 | B2 |
| 8000800 | Takeda et al. | Aug 2011 | B2 |
| 8000805 | Swoyer et al. | Aug 2011 | B2 |
| 8005535 | Gharib et al. | Aug 2011 | B2 |
| 8005549 | Boser et al. | Aug 2011 | B2 |
| 8005550 | Boser et al. | Aug 2011 | B2 |
| 8019423 | Possover | Sep 2011 | B2 |
| 8024047 | Olson et al. | Sep 2011 | B2 |
| 8036756 | Swoyer et al. | Oct 2011 | B2 |
| 8044635 | Peterson | Oct 2011 | B2 |
| 8050769 | Gharib et al. | Nov 2011 | B2 |
| 8055337 | Moffitt et al. | Nov 2011 | B2 |
| 8068912 | Kaula et al. | Nov 2011 | B2 |
| 8083663 | Gross et al. | Dec 2011 | B2 |
| 8103360 | Foster | Jan 2012 | B2 |
| 8116862 | Stevenson et al. | Feb 2012 | B2 |
| 8121701 | Woods et al. | Feb 2012 | B2 |
| 8129942 | Park et al. | Mar 2012 | B2 |
| 8131358 | Moffitt et al. | Mar 2012 | B2 |
| 8140168 | Olson et al. | Mar 2012 | B2 |
| 8145324 | Stevenson et al. | Mar 2012 | B1 |
| 8150530 | Wesselink | Apr 2012 | B2 |
| 8175717 | Haller et al. | May 2012 | B2 |
| 8180451 | Hickman et al. | May 2012 | B2 |
| 8180452 | Shaquer | May 2012 | B2 |
| 8180461 | Mamo et al. | May 2012 | B2 |
| 8214042 | Ozawa et al. | Jul 2012 | B2 |
| 8214048 | Whitehurst et al. | Jul 2012 | B1 |
| 8214051 | Sieracki et al. | Jul 2012 | B2 |
| 8219196 | Torgerson | Jul 2012 | B2 |
| 8219202 | Giftakis et al. | Jul 2012 | B2 |
| 8224460 | Schleicher et al. | Jul 2012 | B2 |
| 8233990 | Goetz | Jul 2012 | B2 |
| 8255057 | Fang et al. | Aug 2012 | B2 |
| 8311636 | Gerber et al. | Nov 2012 | B2 |
| 8314594 | Scott et al. | Nov 2012 | B2 |
| 8332040 | Winstrom | Dec 2012 | B1 |
| 8340786 | Gross et al. | Dec 2012 | B2 |
| 8362742 | Kallmyer | Jan 2013 | B2 |
| 8369943 | Shuros et al. | Feb 2013 | B2 |
| 8386048 | McClure et al. | Feb 2013 | B2 |
| 8417346 | Giftakis et al. | Apr 2013 | B2 |
| 8423146 | Giftakis et al. | Apr 2013 | B2 |
| 8447402 | Jiang et al. | May 2013 | B1 |
| 8447408 | North et al. | May 2013 | B2 |
| 8457756 | Rahman | Jun 2013 | B2 |
| 8457758 | Olson et al. | Jun 2013 | B2 |
| 8467875 | Bennett et al. | Jun 2013 | B2 |
| 8480437 | Dilmaghanian et al. | Jul 2013 | B2 |
| 8494625 | Hargrove | Jul 2013 | B2 |
| 8515545 | Trier | Aug 2013 | B2 |
| 8538530 | Orinski | Sep 2013 | B1 |
| 8543223 | Sage et al. | Sep 2013 | B2 |
| 8544322 | Minami et al. | Oct 2013 | B2 |
| 8549015 | Barolat | Oct 2013 | B2 |
| 8554322 | Olson et al. | Oct 2013 | B2 |
| 8555894 | Schulman et al. | Oct 2013 | B2 |
| 8562539 | Marino | Oct 2013 | B2 |
| 8571677 | Torgerson et al. | Oct 2013 | B2 |
| 8577474 | Rahman et al. | Nov 2013 | B2 |
| 8588917 | Whitehurst et al. | Nov 2013 | B2 |
| 8626314 | Swoyer et al. | Jan 2014 | B2 |
| 8644933 | Ozawa et al. | Feb 2014 | B2 |
| 8655451 | Klosterman et al. | Feb 2014 | B2 |
| 8700175 | Fell | Apr 2014 | B2 |
| 8706254 | Vamos et al. | Apr 2014 | B2 |
| 8725262 | Olson et al. | May 2014 | B2 |
| 8725269 | Nolan et al. | May 2014 | B2 |
| 8738141 | Smith et al. | May 2014 | B2 |
| 8738148 | Olson et al. | May 2014 | B2 |
| 8750985 | Parramon et al. | Jun 2014 | B2 |
| 8761897 | Kaula et al. | Jun 2014 | B2 |
| 8768452 | Gerber | Jul 2014 | B2 |
| 8774912 | Gerber | Jul 2014 | B2 |
| 8855767 | Faltys et al. | Oct 2014 | B2 |
| 8918174 | Woods et al. | Dec 2014 | B2 |
| 8954148 | Labbe et al. | Feb 2015 | B2 |
| 8989861 | Su et al. | Mar 2015 | B2 |
| 9044592 | Imran et al. | Jun 2015 | B2 |
| 9050473 | Woods et al. | Jun 2015 | B2 |
| 9089712 | Joshi et al. | Jul 2015 | B2 |
| 9108063 | Olson et al. | Aug 2015 | B2 |
| 9144680 | Kaula et al. | Sep 2015 | B2 |
| 9149635 | Denison et al. | Oct 2015 | B2 |
| 9155885 | Wei et al. | Oct 2015 | B2 |
| 9166321 | Smith et al. | Oct 2015 | B2 |
| 9168374 | Su | Oct 2015 | B2 |
| 9192763 | Gerber et al. | Nov 2015 | B2 |
| 9197173 | Denison et al. | Nov 2015 | B2 |
| 9199075 | Westlund | Dec 2015 | B1 |
| 9205255 | Strother et al. | Dec 2015 | B2 |
| 9209634 | Cottrill et al. | Dec 2015 | B2 |
| 9216294 | Bennett et al. | Dec 2015 | B2 |
| 9227055 | Wahlstrand et al. | Jan 2016 | B2 |
| 9227076 | Sharma et al. | Jan 2016 | B2 |
| 9238135 | Goetz et al. | Jan 2016 | B2 |
| 9240630 | Joshi | Jan 2016 | B2 |
| 9242090 | Atalar et al. | Jan 2016 | B2 |
| 9244898 | Vamos et al. | Jan 2016 | B2 |
| 9248292 | Trier et al. | Feb 2016 | B2 |
| 9259578 | Torgerson et al. | Feb 2016 | B2 |
| 9259582 | Joshi et al. | Feb 2016 | B2 |
| 9265958 | Joshi et al. | Feb 2016 | B2 |
| 9270134 | Gaddam et al. | Feb 2016 | B2 |
| 9272140 | Gerber et al. | Mar 2016 | B2 |
| 9283394 | Whitehurst et al. | Mar 2016 | B2 |
| 9295851 | Gordon et al. | Mar 2016 | B2 |
| 9308022 | Chitre et al. | Apr 2016 | B2 |
| 9308382 | Strother et al. | Apr 2016 | B2 |
| 9314616 | Wells et al. | Apr 2016 | B2 |
| 9320899 | Parramon et al. | Apr 2016 | B2 |
| 9333339 | Weiner | May 2016 | B2 |
| 9352148 | Stevenson et al. | May 2016 | B2 |
| 9352150 | Stevenson et al. | May 2016 | B2 |
| 9358039 | Kimmel et al. | Jun 2016 | B2 |
| 9364658 | Wechter | Jun 2016 | B2 |
| 9375574 | Kaula et al. | Jun 2016 | B2 |
| 9393423 | Parramon et al. | Jul 2016 | B2 |
| 9399137 | Parker et al. | Jul 2016 | B2 |
| 9409020 | Parker | Aug 2016 | B2 |
| 9415211 | Bradley et al. | Aug 2016 | B2 |
| 9427571 | Sage et al. | Aug 2016 | B2 |
| 9427573 | Gindele et al. | Aug 2016 | B2 |
| 9433783 | Wei et al. | Sep 2016 | B2 |
| 9436481 | Drew | Sep 2016 | B2 |
| 9446245 | Grill et al. | Sep 2016 | B2 |
| 9463324 | Olson et al. | Oct 2016 | B2 |
| 9468755 | Westlund et al. | Oct 2016 | B2 |
| 9471753 | Kaula et al. | Oct 2016 | B2 |
| 9480846 | Strother et al. | Nov 2016 | B2 |
| 9492672 | Vamos et al. | Nov 2016 | B2 |
| 9492675 | Torgerson et al. | Nov 2016 | B2 |
| 9492678 | Chow | Nov 2016 | B2 |
| 9498628 | Kaemmerer et al. | Nov 2016 | B2 |
| 9502754 | Zhao et al. | Nov 2016 | B2 |
| 9504830 | Kaula et al. | Nov 2016 | B2 |
| 9522282 | Chow et al. | Dec 2016 | B2 |
| 9592389 | Moffitt | Mar 2017 | B2 |
| 9610449 | Kaula et al. | Apr 2017 | B2 |
| 9615744 | Denison et al. | Apr 2017 | B2 |
| 9623257 | Olson et al. | Apr 2017 | B2 |
| 9636497 | Bradley et al. | May 2017 | B2 |
| 9643004 | Gerber | May 2017 | B2 |
| 9653935 | Cong et al. | May 2017 | B2 |
| 9656074 | Simon et al. | May 2017 | B2 |
| 9656076 | Trier et al. | May 2017 | B2 |
| 9656089 | Yip et al. | May 2017 | B2 |
| 9675809 | Chow | Jun 2017 | B2 |
| 9687649 | Thacker | Jun 2017 | B2 |
| 9707405 | Shishilla et al. | Jul 2017 | B2 |
| 9713706 | Gerber | Jul 2017 | B2 |
| 9717900 | Swoyer et al. | Aug 2017 | B2 |
| 9724526 | Strother et al. | Aug 2017 | B2 |
| 9731116 | Chen | Aug 2017 | B2 |
| 9737704 | Wahlstrand et al. | Aug 2017 | B2 |
| 9744347 | Chen et al. | Aug 2017 | B2 |
| 9750930 | Chen | Sep 2017 | B2 |
| 9757555 | Novotny et al. | Sep 2017 | B2 |
| 9764147 | Torgerson | Sep 2017 | B2 |
| 9767255 | Kaula et al. | Sep 2017 | B2 |
| 9776002 | Parker et al. | Oct 2017 | B2 |
| 9776006 | Parker et al. | Oct 2017 | B2 |
| 9776007 | Kaula et al. | Oct 2017 | B2 |
| 9782596 | Vamos et al. | Oct 2017 | B2 |
| 9814884 | Parker et al. | Nov 2017 | B2 |
| 9821112 | Olson et al. | Nov 2017 | B2 |
| 9827415 | Stevenson et al. | Nov 2017 | B2 |
| 9827424 | Kaula et al. | Nov 2017 | B2 |
| 9833614 | Gliner | Dec 2017 | B1 |
| 9849278 | Spinelli et al. | Dec 2017 | B2 |
| 9855438 | Parramon et al. | Jan 2018 | B2 |
| 9872988 | Kaula et al. | Jan 2018 | B2 |
| 9878165 | Wilder et al. | Jan 2018 | B2 |
| 9878168 | Shishilla et al. | Jan 2018 | B2 |
| 9882420 | Cong et al. | Jan 2018 | B2 |
| 9884198 | Parker | Feb 2018 | B2 |
| 9889292 | Gindele et al. | Feb 2018 | B2 |
| 9889293 | Siegel et al. | Feb 2018 | B2 |
| 9889306 | Stevenson et al. | Feb 2018 | B2 |
| 9895532 | Kaula et al. | Feb 2018 | B2 |
| 9899778 | Hanson et al. | Feb 2018 | B2 |
| 9901284 | Olsen et al. | Feb 2018 | B2 |
| 9901740 | Drees et al. | Feb 2018 | B2 |
| 9907476 | Bonde et al. | Mar 2018 | B2 |
| 9907955 | Bakker et al. | Mar 2018 | B2 |
| 9907957 | Woods et al. | Mar 2018 | B2 |
| 9924904 | Cong et al. | Mar 2018 | B2 |
| 9931513 | Kelsch et al. | Apr 2018 | B2 |
| 9931514 | Frysz et al. | Apr 2018 | B2 |
| 9950171 | Johanek et al. | Apr 2018 | B2 |
| 9974108 | Polefko | May 2018 | B2 |
| 9974949 | Thompson et al. | May 2018 | B2 |
| 9981121 | Seifert et al. | May 2018 | B2 |
| 9981137 | Eiger | May 2018 | B2 |
| 9987493 | Torgerson et al. | Jun 2018 | B2 |
| 9993650 | Seitz et al. | Jun 2018 | B2 |
| 9999765 | Stevenson | Jun 2018 | B2 |
| 10004910 | Gadagkar et al. | Jun 2018 | B2 |
| 10016596 | Stevenson et al. | Jul 2018 | B2 |
| 10027157 | Labbe et al. | Jul 2018 | B2 |
| 10045764 | Scott et al. | Aug 2018 | B2 |
| 10046164 | Gerber | Aug 2018 | B2 |
| 10047782 | Sage et al. | Aug 2018 | B2 |
| 10052490 | Kaula et al. | Aug 2018 | B2 |
| 10065044 | Sharma et al. | Sep 2018 | B2 |
| 10071247 | Childs | Sep 2018 | B2 |
| 10076661 | Wei et al. | Sep 2018 | B2 |
| 10076667 | Kaula et al. | Sep 2018 | B2 |
| 10083261 | Kaula et al. | Sep 2018 | B2 |
| 10086191 | Bonde et al. | Oct 2018 | B2 |
| 10086203 | Kaemmerer | Oct 2018 | B2 |
| 10092747 | Sharma et al. | Oct 2018 | B2 |
| 10092749 | Stevenson et al. | Oct 2018 | B2 |
| 10095837 | Corey et al. | Oct 2018 | B2 |
| 10099051 | Stevenson et al. | Oct 2018 | B2 |
| 10103559 | Cottrill et al. | Oct 2018 | B2 |
| 10109844 | Dai et al. | Oct 2018 | B2 |
| 10118037 | Kaula et al. | Nov 2018 | B2 |
| 10124164 | Stevenson et al. | Nov 2018 | B2 |
| 10124171 | Kaula et al. | Nov 2018 | B2 |
| 10124179 | Norton et al. | Nov 2018 | B2 |
| 10141545 | Kraft et al. | Nov 2018 | B2 |
| 10173062 | Parker | Jan 2019 | B2 |
| 10179241 | Walker et al. | Jan 2019 | B2 |
| 10179244 | Lebaron et al. | Jan 2019 | B2 |
| 10183162 | Johnson et al. | Jan 2019 | B2 |
| 10188857 | North et al. | Jan 2019 | B2 |
| 10195419 | Shiroff et al. | Feb 2019 | B2 |
| 10206710 | Kern et al. | Feb 2019 | B2 |
| 10213229 | Chitre et al. | Feb 2019 | B2 |
| 10220210 | Walker et al. | Mar 2019 | B2 |
| 10226617 | Finley et al. | Mar 2019 | B2 |
| 10226636 | Gaddam et al. | Mar 2019 | B2 |
| 10236709 | Decker et al. | Mar 2019 | B2 |
| 10238863 | Gross et al. | Mar 2019 | B2 |
| 10238877 | Kaula et al. | Mar 2019 | B2 |
| 10244956 | Kane | Apr 2019 | B2 |
| 10245434 | Kaula et al. | Apr 2019 | B2 |
| 10258800 | Perryman et al. | Apr 2019 | B2 |
| 10265532 | Carcieri et al. | Apr 2019 | B2 |
| 10277055 | Peterson et al. | Apr 2019 | B2 |
| 10293168 | Bennett et al. | May 2019 | B2 |
| 10328253 | Wells | Jun 2019 | B2 |
| 10363419 | Simon et al. | Jul 2019 | B2 |
| 10369275 | Olson et al. | Aug 2019 | B2 |
| 10369370 | Shishilla et al. | Aug 2019 | B2 |
| 10376701 | Kaula et al. | Aug 2019 | B2 |
| 10448889 | Gerber et al. | Oct 2019 | B2 |
| 10456574 | Chen et al. | Oct 2019 | B2 |
| 10471262 | Perryman et al. | Nov 2019 | B2 |
| 10485970 | Gerber et al. | Nov 2019 | B2 |
| 10493282 | Caparso et al. | Dec 2019 | B2 |
| 10493287 | Yoder et al. | Dec 2019 | B2 |
| 10561835 | Gerber | Feb 2020 | B2 |
| 10682521 | Guangqiang et al. | Jun 2020 | B2 |
| 20020040185 | Atalar et al. | Apr 2002 | A1 |
| 20020051550 | Leysieffer | May 2002 | A1 |
| 20020051551 | Leysieffer et al. | May 2002 | A1 |
| 20020140399 | Echarri et al. | Oct 2002 | A1 |
| 20020177884 | Ahn et al. | Nov 2002 | A1 |
| 20030114899 | Woods et al. | Jun 2003 | A1 |
| 20030212440 | Boveja | Nov 2003 | A1 |
| 20040015208 | Haugland et al. | Jan 2004 | A1 |
| 20040098068 | Carbunaru et al. | May 2004 | A1 |
| 20040210290 | Omar-Pasha | Oct 2004 | A1 |
| 20040250820 | Forsell | Dec 2004 | A1 |
| 20040267137 | Peszynski et al. | Dec 2004 | A1 |
| 20040267332 | Kast et al. | Dec 2004 | A1 |
| 20050004619 | Wahlstrand et al. | Jan 2005 | A1 |
| 20050004621 | Boveja et al. | Jan 2005 | A1 |
| 20050021108 | Klosterman et al. | Jan 2005 | A1 |
| 20050075693 | Toy et al. | Apr 2005 | A1 |
| 20050075694 | Schmeling et al. | Apr 2005 | A1 |
| 20050075696 | Forsberg et al. | Apr 2005 | A1 |
| 20050075697 | Olson | Apr 2005 | A1 |
| 20050075698 | Phillips et al. | Apr 2005 | A1 |
| 20050075699 | Olson et al. | Apr 2005 | A1 |
| 20050075700 | Schommer et al. | Apr 2005 | A1 |
| 20050104577 | Matei et al. | May 2005 | A1 |
| 20050187590 | Boveja et al. | Aug 2005 | A1 |
| 20050245839 | Stivoric | Nov 2005 | A1 |
| 20050245996 | Phillips et al. | Nov 2005 | A1 |
| 20060142822 | Tulgar | Jun 2006 | A1 |
| 20060149345 | Boggs et al. | Jul 2006 | A1 |
| 20060200205 | Haller | Sep 2006 | A1 |
| 20060206166 | Weiner | Sep 2006 | A1 |
| 20060253076 | Butts | Nov 2006 | A1 |
| 20070032836 | Thrope et al. | Feb 2007 | A1 |
| 20070228273 | Sun et al. | Oct 2007 | A1 |
| 20070239224 | Bennett et al. | Oct 2007 | A1 |
| 20070257636 | Phillips et al. | Nov 2007 | A1 |
| 20070265675 | Lund et al. | Nov 2007 | A1 |
| 20070293801 | May | Dec 2007 | A1 |
| 20070293914 | Woods et al. | Dec 2007 | A1 |
| 20080065182 | Strother et al. | Mar 2008 | A1 |
| 20080132969 | Bennett et al. | Jun 2008 | A1 |
| 20080154335 | Thrope et al. | Jun 2008 | A1 |
| 20080161874 | Bennett et al. | Jul 2008 | A1 |
| 20080183236 | Gerber | Jul 2008 | A1 |
| 20080288025 | Peterson | Nov 2008 | A1 |
| 20090082835 | Jaax et al. | Mar 2009 | A1 |
| 20100076254 | Jimenez et al. | Mar 2010 | A1 |
| 20100076534 | Mock | Mar 2010 | A1 |
| 20100100158 | Rope et al. | Apr 2010 | A1 |
| 20100174250 | Hu | Jul 2010 | A1 |
| 20100331918 | Digiore et al. | Dec 2010 | A1 |
| 20110257701 | Strother et al. | Oct 2011 | A1 |
| 20110282416 | Hamann et al. | Nov 2011 | A1 |
| 20110301667 | Olson et al. | Dec 2011 | A1 |
| 20120041512 | Weiner | Feb 2012 | A1 |
| 20120046712 | Woods et al. | Feb 2012 | A1 |
| 20120130448 | Woods et al. | May 2012 | A1 |
| 20120139485 | Olson et al. | Jun 2012 | A1 |
| 20120276854 | Joshi et al. | Nov 2012 | A1 |
| 20120276856 | Joshi et al. | Nov 2012 | A1 |
| 20130004925 | Labbe et al. | Jan 2013 | A1 |
| 20130006330 | Wilder et al. | Jan 2013 | A1 |
| 20130006331 | Weisgarber et al. | Jan 2013 | A1 |
| 20130105115 | Kallmyer et al. | May 2013 | A1 |
| 20130150925 | Vamos et al. | Jun 2013 | A1 |
| 20130197608 | Eiger | Aug 2013 | A1 |
| 20130207863 | Joshi | Aug 2013 | A1 |
| 20130253614 | Knifong, Sr. | Sep 2013 | A1 |
| 20130310894 | Trier | Nov 2013 | A1 |
| 20130331638 | Cameron et al. | Dec 2013 | A1 |
| 20130331909 | Gerber | Dec 2013 | A1 |
| 20140070761 | Labbe et al. | Mar 2014 | A1 |
| 20140180365 | Perryman et al. | Jun 2014 | A1 |
| 20140194802 | Check | Jul 2014 | A1 |
| 20140222112 | Fell | Aug 2014 | A1 |
| 20140237806 | Smith et al. | Aug 2014 | A1 |
| 20140277270 | Parramon et al. | Sep 2014 | A1 |
| 20140371802 | Mashiach et al. | Dec 2014 | A1 |
| 20150088227 | Shishilla et al. | Mar 2015 | A1 |
| 20150214604 | Zhao et al. | Jul 2015 | A1 |
| 20160199657 | Jiang et al. | Jul 2016 | A1 |
| 20170197079 | Illegems et al. | Jul 2017 | A1 |
| 20170340878 | Wahlstrand et al. | Nov 2017 | A1 |
| 20180021587 | Strother et al. | Jan 2018 | A1 |
| 20180036477 | Olson et al. | Feb 2018 | A1 |
| 20190269918 | Parker | Sep 2019 | A1 |
| 20190351244 | Shishilla et al. | Nov 2019 | A1 |
| 20190358395 | Olson et al. | Nov 2019 | A1 |
| Number | Date | Country |
|---|---|---|
| 520440 | Sep 2011 | AT |
| 4664800 | Nov 2000 | AU |
| 5123800 | Nov 2000 | AU |
| 2371378 | Nov 2000 | CA |
| 2554676 | Sep 2005 | CA |
| 101234230 | Aug 2008 | CN |
| 101259302 | Sep 2008 | CN |
| 101896224 | Nov 2010 | CN |
| 102724017 | Oct 2012 | CN |
| 104487131 | Apr 2015 | CN |
| 104511091 | Apr 2015 | CN |
| 105163799 | Dec 2015 | CN |
| 107427685 | Dec 2017 | CN |
| 3146182 | Jun 1983 | DE |
| 0656218 | Jun 1995 | EP |
| 1205004 | May 2002 | EP |
| 1680182 | Jul 2006 | EP |
| 2243509 | Oct 2010 | EP |
| 1680182 | May 2013 | EP |
| 1904153 | Apr 2015 | EP |
| 3242721 | Nov 2017 | EP |
| 3242721 | Sep 2019 | EP |
| 2395128 | Feb 2013 | ES |
| 1098715 | Mar 2012 | HK |
| 2002253685 | Sep 2002 | JP |
| 2007268293 | Oct 2007 | JP |
| 4125357 | Jul 2008 | JP |
| 2010527569 | Aug 2010 | JP |
| 2018501021 | Jan 2018 | JP |
| 9820933 | May 1998 | WO |
| 9918879 | Apr 1999 | WO |
| 9934870 | Jul 1999 | WO |
| 9942173 | Aug 1999 | WO |
| 0056677 | Sep 2000 | WO |
| 0065682 | Nov 2000 | WO |
| 0069012 | Nov 2000 | WO |
| 0183029 | Nov 2001 | WO |
| 0209808 | Feb 2002 | WO |
| 2004021876 | Mar 2004 | WO |
| 2004103465 | Dec 2004 | WO |
| 2005079295 | Sep 2005 | WO |
| 2005081740 | Sep 2005 | WO |
| 2008021524 | Feb 2008 | WO |
| 2011059565 | May 2011 | WO |
| 2016112401 | Jul 2016 | WO |
| Entry |
|---|
| US 9,601,939 B2, 03/2017, Cong et al. (withdrawn) |
| Ke et al., Design on Experiment on Transcutaneous Energy Charging System in Implantable Medical Device, Chinese Journal of Scientific Instrument, vol. 34, No. 12, Dec. 15, 2013, pp. 2846-2853. |
| Bu-802a: How Does Rising Internal Resistance Affect Performance? Understanding the Importance of Low Conductivity, BatteryUniversity.com, Available Online at https://batteryuniversity.com/learn/article/rising_internal_resistance, Accessed from Internet on: May 15, 2020, 10 pages. |
| DOE Handbook: Primer on Lead-Acid Storage Batteries, U.S. Dept. of Energy, Available Online at: htt12s://www.stan dards.doe.gov/standards- documents/I 000/1084-bhdbk-1995/@@images/file, Sep. 1995, 54 pages. |
| Medical Electrical Equipment—Part 1: General Requirements for Safety, British Standard, BS EN 60601-1:1990-BS5724-1:1989, Mar. 1979, 200 pages. |
| Summary of Safety and Effectiveness, Medtronic InterStim System for Urinary Control, Apr. 15, 1999, pp. 1-18. |
| The Advanced Bionics PRECISION™ Spinal Cord Stimulator System, Advanced Bionics Corporation, Apr. 27, 2004, pp. 1-18. |
| UL Standard for Safety for Medical and Dental Equipment, UL 544, 4th edition, Dec. 30, 1998, 128 pages. |
| Barnhart et al., “A Fixed-Rate Rechargeable Cardiac Pacemaker”, APL Technical Digest, Jan.-Feb. 1970, pp. 2-9. |
| Benditt et al., “A Combined Atrial/Ventricular Lead for Permanent Dual-Chamber Cardiac Pacing Applications”, Chest, vol. 83, No. 6, Jun. 1983, pp. 929-931. |
| Bosch et al., “Sacral (S3) Segmental Nerve Stimulation as a Treatment for Urge Incontinence in Patients with Detrusor Instability: Results of Chronic Electrical Stimulation Using an Implantable Neural Prosthesis”, The Journal of Urology, vol. 154, No. 2, Aug. 1995, pp. 504-507. |
| Boyce et al., “Research Related to the Development of an Artificial Electrical Stimulator for the Paralyzed Human Bladder: a Review”, The Journal of Urology, vol. 91, No. 1, Jan. 1964, pp. 41-51. |
| Bradley et al., “Further Experience With the Radio Transmitter Receiver Unit for the Neurogenic Bladder”, Journal of Neurosurgery, vol. 20, No. 11, Nov. 1963, pp. 953-960. |
| Broggi et al., “Electrical Stimulation of the Gasserian Ganglion for Facial Pain: Preliminary Results”, Acta Neurochirurgica, vol. 39, 1987, pp. 144-146. |
| Cameron et al., “Effects of Posture on Stimulation Parameters in Spinal Cord Stimulation”, Neuromodulation, vol. 1, No. 4, Oct. 1998, pp. 177-183. |
| Connelly et al., “Atrial Pacing Leads Following Open Heart Surgery: Active or Passive Fixation?”, Pacing and Clinical Electrophysiology, vol. 20, No. 10, Oct. 1997, pp. 2429-2433. |
| Fischell , “The Development of Implantable Medical Devices at the Applied Physics Laboratory”, Johns Hopkins APL Technical Digest, vol. 13 No. 1, 1992, pp. 233-243. |
| Gaunt et al., “Control of Urinary Bladder Function With Devices: Successes and Failures”, Progress in Brain Research, vol. 152, 2006, pp. 1-24. |
| Ghovanloo et al., “A Small Size Large Voltage Compliance Programmable Current Source for Biomedical Implantable Microstimulators”, Proceedings of the 25th Annual International Conference of the IEEE EMBS, Sep. 17-21, 2003, pp. 1979-1982. |
| Helland , “Technical Improvements to be Achieved by the Year 2000: Leads and Connector Technology”, Rate Adaptive Cardiac Pacing, Springer Verlag, 1993, pp. 279-292. |
| Hidefjall , “The Pace of Innovation—Patterns of Innovation in the Cardiac Pacemaker Industry”, Linkoping University Press, 1997, 398 pages. |
| Ishihara et al., “A Comparative Study of Endocardial Pacemaker Leads”, Cardiovascular Surgery, Nagoya Ekisaikai Hospital, 1st Dept. of Surgery, Nagoya University School of Medicine, 1981, pp. 132-135. |
| Jonas et al., “Studies on the Feasibility of Urinary Bladder Evacuation by Direct Spinal Cord Stimulation. I. Parameters of Most Effective Stimulation”, Investigative urology, vol. 13, No. 2, 1975, pp. 142-150. |
| Kakuta et al., “In Vivo Long Term Evaluation of Transcutaneous Energy Transmission for Totally Implantable Artificial Heart”, ASAIO Journal, Mar.-Apr. 2000, pp. 1-2. |
| Kester et al., “Voltage-to-Frequency Converters”, Available Online at: https://www.analog.com/media/cn/training-seminars/tutorials/MT-028.pdf, 7 pages. |
| Lazorthes et al., “Chronic Stimulation of the Gasserian Ganglion for Treatment of Atypical Facial Neuralgia”, Pacing and Clinical Electrophysiology, vol. 10, Jan.-Feb. 1987, pp. 257-265. |
| Lewis et al., “Early Clinical Experience with the Rechargeable Cardiac Pacemaker”, The Annals of Thoracic Surgery, vol. 18, No. 5, Nov. 1974, pp. 490-493. |
| Love et al., “Experimental Testing of a Permanent Rechargeable Cardiac Pacemaker”, The Annals of Thoracic Surgery, vol. 17, No. 2, Feb. 1, 1974, pp. 152-156. |
| Love , “Pacemaker Troubleshooting and Follow-up”, Clinical Cardiac Pacing, Defibrillation, and Resynchronization Therapy, Chapter 24, 2007, pp. 1005-1062. |
| Madigan et al., “Difficulty of Extraction of Chronically Implanted Tined Ventricular Endocardial Leads”, Journal of the American College of Cardiology, vol. 3, No. 3, Mar. 1984, pp. 724-731. |
| Meglio , “Percutaneously Implantable Chronic Electrode for Radiofrequency Stimulation of the Gasserian Ganglion. A Perspective in the Management of Trigeminal Pain”, Acta Neurochirurgica, vol. 33, 1984, pp. 521-525. |
| Meyerson , “Alleviation of Atypical Trigeminal Pain by Stimulation of the Gasserian Ganglion via an Implanted Electrode”, Acta Neurochirurgica Suppiementum , vol. 30, 1980, pp. 303-309. |
| Mitamura et al., “Development of Transcutaneous Energy Transmission System”, Available Online at https://www.researchgate.net/publication/312810915 Ch.28, Jan. 1988, pp. 265-270. |
| Nakamura et al., “Biocompatibility and Practicality Evaluations of Transcutaneous Energy Transmission Unit for the Totally Implantable Artifical Heart System”, Journal of Artificial Organs, vol. 27, No. 2, 1998, pp. 347-351. |
| Nashold et al., “Electromicturition in Paraplegia. Implantation of a Spinal Neuroprosthesis”, Arch Surg., vol. 104, Feb. 1972, pp. 195-202. |
| Painter et al., “Implantation of an Endocardial Tined Lead to Prevent Early Dislodgement”, The Journal of Thoracic and Cardiovascular Surgery, vol. 77, No. 2, Feb. 1979, pp. 249-251. |
| Perez , “Lead-Acid Battery State of Charge vs. Voltage”, Available Online at http://www.rencobattery.com/resources/SOC vs-Voltage.pdf, Aug.-Sep. 1993, 5 pages. |
| Schaldach et al., “A Long-Lived, Reliable, Rechargeable Cardiac Pacemaker”, Engineering in Medicine, vol. 1: Advances in Pacemaker Technology, 1975, 34 pages. |
| Scheuer-Leeser et al., “Polyurethane Leads: Facts and Controversy”, PACE, vol. 6, Mar.-Apr. 1983, pp. 454-458. |
| Smith , “Changing Standards for Medical Equipment”, UL 544 and UL 187 vs. UL 2601 (“Smith”), 2002, 8 pages. |
| Tanagho et al., “Bladder Pacemaker: Scientific Basis and Clinical Future”, Urology, vol. 20, No. 6, Dec. 1982, pp. 614-619. |
| Tanagho , “Neuromodulation and Neurostimulation: Overview and Future Potential”, Translational Androl Urol, vol. 1, No. 1, 2012, pp. 44-49. |
| Torres et al., “Electrostatic Energy-Harvesting and Battery-Charging CMOS System Prototype”, Available Online at: http://rincon mora.gatech.edu/12ublicat/jrnls/tcasi09_hrv_sys.pdf, pp. 1-10. |
| Young , “Electrical Stimulation of the Trigeminal Nerve Root for the Treatment of Chronic Facial Pain”, Journal of Neurosurgery, vol. 83, No. 1, Jul. 1995, pp. 72-78. |
| U.S. Appl. No. 62/038,122, filed Aug. 15, 2014. |
| U.S. Appl. No. 62/038,131, filed Aug. 15, 2014. |
| U.S. Appl. No. 62/041,611, filed Aug. 25, 2014. |
| U.S. Appl. No. 62/101,666, filed Jan. 9, 2015. |
| U.S. Appl. No. 62/101,782, filed Jan. 9, 2015. |
| U.S. Appl. No. 62/101,884, filed Jan. 9, 2015. |
| U.S. Appl. No. 62/101,888, filed Jan. 9, 2015. |
| U.S. Appl. No. 62/101,897, filed Jan. 9, 2015. |
| U.S. Appl. No. 62/101,899, filed Jan. 9, 2015. |
| Number | Date | Country | |
|---|---|---|---|
| 20200338357 A1 | Oct 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62101884 | Jan 2015 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14992977 | Jan 2016 | US |
| Child | 16871738 | US |
